Form 4 Vertex Pharmaceuticals Inc For: 30 June
- Investing.com
- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Vertex Pharmaceuticals Inc (VRTX)
The Vertex share price today is 500.46, view NASDAQ VRTX stock exchange data. Track the latest Vertex share price with real-time updates on VRTX stock performance including market cap, day range, 52-week range and dividend yield. Access VRTX charts, earnings dates and analyst estimates to support your investment decisions.
500.46
+3.73(+0.75%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
495.00
502.71
52 wk Range
362.50
507.92
VRTX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
495.00502.71
52 wk Range
362.50507.92
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
VRTX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
548.69
Upside
+9.64%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
RSI suggests the stock is in overbought territory
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Analyst Ratings
27 Buy
4 Hold
2 Sell
Ratings:
33 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 548.69
(+9.64% Upside)
Vertex Pharmaceuticals Inc SWOT Analysis
CF Market Dominance | Vertex's stronghold in cystic fibrosis treatments underpins its financial health, with $11.4 billion in revenue and 10.5% growth, fueling expansion into new therapeutic areas |
Pipeline Potential | Delve into Vertex's diversification strategy, including promising developments in acute pain management, renal diseases, and type 1 diabetes treatments |
Market Valuation | Analysts set an average price target of $491, reflecting optimism about Vertex's growth prospects despite recent earnings falling short of expectations |
Strategic Challenges | Explore Vertex's approach to overcoming competition in pain management and navigating the risks associated with expanding beyond its core cystic fibrosis business |
Vertex Pharmaceuticals Inc Earnings Call Summary for Q1/2026
- Q1 2026 EPS of $4.47 beat estimates by 3.23%, though revenue of $2.99B missed forecasts by 1.32%, growing 8% year-over-year.
- Operating income rose 11% to $1.31B; company maintains strong balance sheet with $13B in cash and investments.
- New products CASGEVY and JOURNAVX drove growth alongside CF portfolio; executives emphasized continued innovation and market expansion.
- Company projects Q2 2026 EPS of $4.75 and FY 2026 revenue of $13.02B, though 10 analysts revised earnings downward for upcoming period.
- Stock rose 0.1% aftermarket to $424.02; VX-522 program discontinued due to patient safety concerns, focus shifting to alternative solutions.
Last Updated: 05-05-2026, 03:30 am
Read Full TranscriptEarnings
Latest Release
04-05-2026
EPS / Forecast
4.47 / 4.33
Revenue / Forecast
2.99B / 3.03B
Compare VRTX to Peers and Sector
Metrics to compare | VRTX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipVRTXPeersSector | |
|---|---|---|---|---|
P/E Ratio | 29.3x | 21.3x | −0.4x | |
PEG Ratio | 0.05 | −0.52 | 0.00 | |
Price/Book | 6.6x | 3.6x | 2.6x | |
Price / LTM Sales | 10.4x | 2.6x | 3.0x | |
Upside (Analyst Target) | 11.7% | 0.0% | 53.6% | |
Fair Value Upside | Unlock | 10.3% | 7.6% | Unlock |
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Vertex (VRTX) Share Price Today?
The Vertex share price today is 500.46.
What is the current Vertex (VRTX) share price and day range?
As of 01-07-2026, the Vertex share price is 500.46, with a previous close of 496.73. The share price has ranged from 495.00 to 502.71 today, while the 52-week range spans from 362.50 to 507.92.
What Is the Vertex Market Cap?
As of today, Vertex market cap is 127.04B.
What Is the Vertex (VRTX) Share Price Target?
The average 12-month share price target for Vertex is 548.69, with a high estimate of 641 and a low estimate of 330. 27 analysts recommend buying, while 2 suggest selling, with an overall rating of Buy and +9.64% Upside potential.
What Is Vertex's Earnings Per Share (TTM)?
The Vertex EPS (TTM) is 16.86.
When Is the Next Vertex Earnings Date?
Vertex will release its next earnings report on 30-07-2026.
From a Technical Analysis Perspective, Is VRTX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
What Stock Exchange Does Vertex Trade On?
Vertex is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Vertex?
The stock symbol for Vertex is "VRTX."
How Many Times Has Vertex Stock Split?
Vertex has split 1 times.
How Many Employees Does Vertex Have?
Vertex has 6400 employees.
What Is the VRTX Premarket Price?
VRTX's last pre-market stock price is 501.47. The pre-market share volume is 2,750.00, and the stock has changed by 4.74, or 0.95%.
What Is the VRTX After Hours Price?
VRTX's last after hours stock price is 496.45, the stock has changed by -0.29, or -0.06%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.